PTEN and cancer: This threshold assumed that the most frequently enrolled patients are expected to be those with breast cancers, reflecting the higher prevalence of germline PTEN mutations observed in patients with breast cancers compared with other types of cancer [28], and the ORR for best supportive care or placebo being <10% in patients with metastatic breast cancers [29].